These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 18338434)

  • 21. Analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and quality of life at 24 weeks.
    Sayana S; Prosser P; Ricaurte JC; Sanchez S; Hamwi G; Hershey-Weber J; Chien C; Easley A; Nguyen T; Wilson L; Khanlou H
    J Int Assoc Physicians AIDS Care (Chic); 2009; 8(2):85-6. PubMed ID: 19369697
    [No Abstract]   [Full Text] [Related]  

  • 22. [Entry inhibitors. Ring-free for a new principle of action].
    Rümmelein N; Jäger H
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():16-20. PubMed ID: 15011578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Localized amyloidosis at the site of enfuvirtide injection.
    Morilla ME; Kocher J; Harmaty M
    Ann Intern Med; 2009 Oct; 151(7):515-6. PubMed ID: 19805777
    [No Abstract]   [Full Text] [Related]  

  • 24. Trimeris, Roche pull no-needle Fuzeon bid.
    AIDS Read; 2007 Dec; 17(12):581. PubMed ID: 18178973
    [No Abstract]   [Full Text] [Related]  

  • 25. Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients.
    Salzberger B; Däumer M; Gute P; Jaeger H; Knechten H; van Lunzen J; Mauss S; Mayr C; Moll A; Plettenberg A; Rockstroh J; Staszewski S; Stellbrink HJ; Stoll M; Sturmer M
    Eur J Med Res; 2007 Mar; 12(3):93-102. PubMed ID: 17507306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Initiation of therapy with a subcutaneously administered antiretroviral in treatment-experienced HIV-infected patients: understanding physician and patient perspectives.
    Horne R; Cooper V; Fisher M
    AIDS Care; 2008 Oct; 20(9):1029-38. PubMed ID: 18825512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serious infection from Staphylococcus aureus in 2 HIV-infected patients receiving fusion inhibitor therapy.
    Gaughan EM; Ritter ML; Kumar PN; Timpone JG
    AIDS Read; 2008 May; 18(5):266-8. PubMed ID: 18589482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [HIV infections: further options for combination therapy].
    Hildegard K
    Dtsch Med Wochenschr; 2003 Jul; 128(28-29):1523. PubMed ID: 12899165
    [No Abstract]   [Full Text] [Related]  

  • 29. Short communication safety, tolerability and pharmacokinetics of enfuvirtide administered by a needle-free injection system compared with subcutaneous injection.
    Gottlieb M; Thommes JA;
    Antivir Ther; 2008; 13(5):723-7. PubMed ID: 18771056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. T-20 (Fuzeon) gets priority review.
    AIDS Treat News; 2002 Oct; (384):4-5. PubMed ID: 12434762
    [No Abstract]   [Full Text] [Related]  

  • 31. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enfuvirtide (Fuzeon) for HIV Infection.
    Med Lett Drugs Ther; 2003 Jun; 45(1159):49-50. PubMed ID: 12817195
    [No Abstract]   [Full Text] [Related]  

  • 33. [Enfuvirtide in HIV patients: a nursing guideline for medication management].
    Bigler S; Nicca D; Spirig R;
    Pflege; 2009 Feb; 22(1):29-38. PubMed ID: 19173176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical trials for enfuvirtide (Fuzeon, T-20).
    Crabb C
    AIDS; 2003 Nov; 17(17):N13-4. PubMed ID: 15065580
    [No Abstract]   [Full Text] [Related]  

  • 35. Use of darunavir and enfuvirtide in a pregnant woman.
    Sued O; Lattner J; Gun A; Patterson P; Abusamra L; Cesar C; Fink V; Krolewiecki A; Cahn P
    Int J STD AIDS; 2008 Dec; 19(12):866-7. PubMed ID: 19050223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administration.
    Loutfy MR; Harris M; Raboud JM; Antoniou T; Kovacs C; Shen S; Dufresne S; Smaill F; Rouleau D; Rachlis A; Gough K; Lalonde R; Tsoukas C; Trottier B; Walmsley SL; Montaner JS
    HIV Med; 2007 Oct; 8(7):427-32. PubMed ID: 17760734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects.
    Thompson M; DeJesus E; Richmond G; Wheeler D; Flaherty J; Piliero P; True A; Chiu YY; Zhang Y; McFalls E; Miralles GD; Patel IH
    AIDS; 2006 Feb; 20(3):397-404. PubMed ID: 16439873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postmarketing use of enfuvirtide in veterans: provider compliance with criteria for use, overall efficacy, and tolerability.
    Belperio PS; Mole LA; Halloran J; Boothroyd DB; Thomas IC; Backus LI
    Ann Pharmacother; 2008 Nov; 42(11):1573-80. PubMed ID: 18940919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Enfuvirtida (Fuzeon). Laboratory: Roche & Trimeris].
    Moreno Alvarez PJ
    Farm Hosp; 2003; 27(4):271-2. PubMed ID: 12966457
    [No Abstract]   [Full Text] [Related]  

  • 40. Phase II begins for T-20.
    AIDS Patient Care STDS; 1999 Sep; 13(9):567-8. PubMed ID: 10813040
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.